QUESTION 1 You are a pharmaceutical scientist employed by a pharmaceutical company that is developing a compound called DDZ. The structure of DOZ is provided below along with a table of general properties Chemical structure of DDZ Properties of DDZ DDZ is currently undergoing Phase 1 clinical evaluation in humans. You are part of the scientific team developing DDZ and you are responsible for overseeing issues related to pharmaceutical analysis, preformulation screening, and pharmacokinetic evaluation of DDZ. Please answer the following questions Pharmacevtical Analysis 1. Recomenend analyical METHOOS for the quantitative determination of the DDZ Support your choice by explaining WHY you are making that recommendation. 2. DDZ is to be separated frem plasma with a solid phase extraction technique. Outine a solid phase extraction PROCEDUAE for this drug from the plasma. (Please remember to mention type of solid phase, solvents, 3. Suggest an HPLC method for the quantitative determination of DDZ. (Please remember to mention type of stationary phase, mobile phase, detector. 4. There are several criteria used to validate an analytical method. Mention one of